Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Sells 6,000 Shares

Bobak Azamian, President/CEO and Board Chair of Tarsus Pharmaceuticals, sold 6,000 shares of common stock at $50 per share on March 24, 2025, according to a Form 4 filing.

Summary

• On March 24, 2025, Bobak R. Azamian, the President/CEO and Board Chair of Tarsus Pharmaceuticals, sold 6,000 shares of the company's common stock.
• The sale was executed at a price of $50 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following the transaction, Azamian directly owns 53,635 shares and indirectly owns 824,106 shares through the Bobak Azamian Living Trust established April 16, 2018.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

Insider sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. However, large or frequent sales can sometimes be viewed negatively by investors.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although the pre-planned nature of the sale mitigates this concern.

Key Dates

Keywords

Form 4, Tarsus Pharmaceuticals, Bobak Azamian, stock sale, Rule 10b5-1, insider trading